<DOC>
	<DOC>NCT00278941</DOC>
	<brief_summary>The purpose of this study is to determine safety &amp; efficacy of SEROQUEL SR™ in the treatment of major depressive disorder compared to placebo &amp; to evaluate quality of sleep, overall quality of life, and effect, if any, on anxiety and satisfaction PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Documented clinical diagnosis according to the DSMIV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision) meeting criteria 296.2x Major Depressive Disorder, Single Episode, or 296.3x Major Depressive Disorder, Patients with a DSMIV Axis I disorder other than MDD w/in 6 months of enrollment, Patients with a diagnosis of DSMIV Axis II disorder which has a major impact on the patients current psychiatric status. Patients whose current episode of depression&gt;12 months or &lt;4 weeks from enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Seroquel SR™</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>